- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01267877
Patient Perception of Mammogram Guidelines
January 4, 2017 updated by: University of Massachusetts, Worcester
The purpose of this study was to determine attitudes regarding the 2009 USPSTF Guidelines for breast cancer screening for women in their 40's and assess the effect of one of two newspaper articles on their attitudes.
The population studied was women seeing their private gynecologist for annual exams in the 39-49 year old age group.
Study Overview
Status
Completed
Conditions
Detailed Description
Subjects completed a baseline questionnaire listing demographics, previous experience with mammograms, and acquaintances with breast cancer.
They then were randomly assigned one of two articles (one favorable and one unfavorable) that had been published in the newspaper regarding the USPSTF breast cancer screening guidelines.
Their attitudes towards the safety of the guidelines and their willingness to comply with them was then measured.
Study Type
Interventional
Enrollment (Actual)
247
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Auburn, Massachusetts, United States, 01501
- UMassMemorial Medical Group- Auburn Gyn
-
Shrewsbury, Massachusetts, United States, 01545
- Shrewsbury Ob-Gyn
-
Shrewsbury, Massachusetts, United States, 01545
- UMassMemorial Medical Group- OB-GYN
-
Worcester, Massachusetts, United States, 01608
- Women's Health of Central Mass
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
39 years to 49 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- women aged 39-49 seeing their gynecologist for routine preventive care
Exclusion Criteria:
- women not aged 39-49
- women with breast cancer
- women not able to read English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Guideline unfavorable article
|
article title: "Taking a hit on healthcare- why that's women's work"
Other Names:
|
|
Active Comparator: Guideline favorable article
|
read "A Backlash of Mistrust"
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Willingness to forgo mammograms from age 40-49
Time Frame: within 15 minutes of completion of reading assigned article
|
within 15 minutes of completion of reading assigned article
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Do you feel that the mammogram recommendations safe?
Time Frame: within 15 minutes of completion of reading assigned article
|
within 15 minutes of completion of reading assigned article
|
|
Do attitudes regarding the breast cancer screening guidelines differ by acquaintance with breast cancer?
Time Frame: within 15 minutes of completion of reading assigned article
|
within 15 minutes of completion of reading assigned article
|
|
Does willingness to forgo mammograms in their 40's differ by previous "false alarms" with mammography?
Time Frame: within 15 minutes of completion of reading assigned article
|
within 15 minutes of completion of reading assigned article
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Dale Magee, M.D., M.S., University of Massachusetts, Worcester
- Study Director: AuTumn Davidson, M.D., University of Massachusetts, Worcester
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
December 22, 2010
First Submitted That Met QC Criteria
December 28, 2010
First Posted (Estimate)
December 29, 2010
Study Record Updates
Last Update Posted (Estimate)
January 5, 2017
Last Update Submitted That Met QC Criteria
January 4, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- OBGYN13730
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on read unfavorable article prior to answering questions
-
Boston Children's HospitalNational Human Genome Research Institute (NHGRI)Active, not recruitingGenetic Disease | Genetic PredispositionUnited States